Decide | Jotup

#ThxBirthControl Campaign Continues to Empower and Inform Amidst Challenges in Reproductive Health

Retrieved on:

Tuesday, November 14, 2023

WASHINGTON, Nov. 14th, 2023 /PRNewswire-PRWeb/ -- For over a decade, Power to Decide's annual #ThxBirthControl campaign, which happens on November 15th this year, has been a beacon of empowerment, sparking conversations and promoting awareness about contraception and all that it makes possible. In 2021, the campaign was honored with the People's Voice Webby Award, solidifying its impact in leading a positive national conversation about birth control and its benefits. Each year #ThxBirthControl trends nationally across social media and garners 99% positive sentiment; elevating tens of thousands of supportive stories and voices.

Key Points:

Young people are telling us that they do not have the birth control information they want and need.
By sharing so many stories about all that birth control makes possible, #ThxBirthControl brings birth control information directly to young people where they are – on social media.
"Thanks, Birth Control is a movement that's needed now more than ever," said Power to Decide's CEO, Dr. Raegan McDonald-Mosley.
Social Media Education: The survey highlights the role of social media in providing young people with information about birth control.

Madrona Venture Labs Raises $11 Million to Power The Next Wave of AI Founders

Retrieved on:

Wednesday, June 21, 2023

Madrona Venture Labs (MVL) , a Seattle-based startup studio, today announces $11 million for its fifth fund.

Key Points:

Madrona Venture Labs (MVL) , a Seattle-based startup studio, today announces $11 million for its fifth fund.
Madrona led the financing round and was joined by a group of successful founders and operators.
"MVL is the 'day one' in Madrona's continuum of supporting founders over the long run of their startup journey," said Hope Cochran, Managing Director of Madrona.
"Founders building a company with MVL get the full support of the Madrona team and the experienced builders joining their fund."

IMV Inc. Announces Second Quarter 2022 Financial and Operational Results

Retrieved on:

Thursday, August 11, 2022

Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical Trials, Clinical trial, TSX, Department, Patient, Pembrolizumab, CD4, KOL, Memorial Sloan Kettering Cancer Center, US, MD, SEDAR, Immune system, IMV, Terminology, Safety, American Association, Associate professor, B-cell lymphoma, Obstetrics, American Association for Cancer Research, Aggression, Cancer, Gynaecology, Corporation, Survivin, Horizon, Immunotherapy, Webcast, Ovarian cancer, Forward-looking statement, CD8, CA, EDGAR, Bladder cancer, Mission statement, AACR, DPX, DLBCL, Compliance, Stanford University, Decide, Hematological Cancer Research Investment and Education Act, Company, Twitter, CPA, Research, LinkedIn, Department of Obstetrics and Gynecology (Massachusetts General Hospital), Pharmaceutical industry, Vaccine, Reinsurance, EU, Nasdaq

IMV Inc. (Nasdaq: IMV; TSX: IMV) (IMV or the Company), a clinical-stage biopharmaceutical company developing a portfolio of immune-educating therapies based on its novel DPX platform to treat solid and hematologic cancers, today announced its financial and operational results and provided an update for the second quarter ended June 30, 2022.

Key Points:

IMV Inc. (Nasdaq: IMV; TSX: IMV) (IMV or the Company), a clinical-stage biopharmaceutical company developing a portfolio of immune-educating therapies based on its novel DPX platform to treat solid and hematologic cancers, today announced its financial and operational results and provided an update for the second quarter ended June 30, 2022.
IMV continues to enroll patients in the VITALIZE Phase 2B clinical trial, advancing its lead compound, maveropepimut-S (MVP-S) in a global, multi-center confirmatory trial.
IMV is on track to complete enrollment of the first stage of the study in H1 2023.
IMV Inc. assumes no responsibility to update forward-looking statements in this press release except as required by law.

Decide Proudly Announces Opening of New Austin, Texas, Hub

Retrieved on:

Wednesday, June 15, 2022

Growth, Decision, Nash House (409 East 6th Street, Little Rock, Arkansas), CEO, Magic, Foot, Decide, GLOBE, Technology, Risk management, Management

AUSTIN, Texas, June 15, 2022 (GLOBE NEWSWIRE) -- Decide Technologies Inc. (Decide) is proud to announce that the company has opened a new employee hub in Austin, Texas.

Key Points:

AUSTIN, Texas, June 15, 2022 (GLOBE NEWSWIRE) -- Decide Technologies Inc. (Decide) is proud to announce that the company has opened a new employee hub in Austin, Texas.
The office is located in the East Austin neighborhood, which is among the fastest growing areas in the city.
Decide allows employees to work from anywhere with no in-person requirements.
The Austin hub is located at 1408 East 6th Street and is open for use by Decide employees.

IMV to Showcase its DPX® Delivery Technology in Two Presentations at the AACR Annual Meeting 2022

Retrieved on:

Wednesday, March 9, 2022

IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX platform to treat solid and hematologic cancers, today announced that the Company will showcase its DPX delivery technology in two presentations at the American Association for Cancer Research (AACR) Annual Meeting, taking place April 8-13, 2022, in New Orleans, Louisiana.

Key Points:

IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX platform to treat solid and hematologic cancers, today announced that the Company will showcase its DPX delivery technology in two presentations at the American Association for Cancer Research (AACR) Annual Meeting, taking place April 8-13, 2022, in New Orleans, Louisiana.
Through a differentiated mechanism of action, the DPX platform delivers instruction to the immune system to generate a specific, robust, and persistent immune response.
IMVs lead candidate, maveropepimut-S (MVP-S), delivers antigenic peptides from survivin, a well-recognized cancer antigen commonly overexpressed in advanced cancers.
IMV is also developing a second immunotherapy leveraging the DPX immune delivery platform, DPX-SurMAGE.

LockerDome Rebrands as Decide, Introduces Machine Learning and Decision Platform Decision Marketplace℠ to Power Digital Ads

Retrieved on:

Monday, February 7, 2022

GLOBE, Industry, AI, Decision, Decision-making, Technology, Advertising, CEO, Environment, Ecosystem, Machine learning, Online shopping, Risk management, Retail, Decide

As a part of this relaunch, Decide is introducing its home-grown, machine learning and decision platform, the Decision Marketplace, to help navigate the tectonic shifts from the deprecation of third-party cookies to the growing ubiquity of unified, first-price auctions currently impacting the digital advertising industry.

Key Points:

As a part of this relaunch, Decide is introducing its home-grown, machine learning and decision platform, the Decision Marketplace, to help navigate the tectonic shifts from the deprecation of third-party cookies to the growing ubiquity of unified, first-price auctions currently impacting the digital advertising industry.
Successfully navigating these waters is not just dependent on the rapid development and iteration of machine learning models but also on our ability to automate intelligent decisions in the real world.
The Decision Marketplace now provides Decides analysts an entirely composable environment in which they can build, train, test, and deploy machine learning models in minutes.
Decide offers better ad formats, better metrics, better budgeting, and better machine learning decisions to deliver quantifiable results for brands and publishers.